发明名称 DIABETES BIOMARKERS
摘要 A new markers for insulin production decline in Type 1 diabetes has been found in the ratio the CD4 naïve (CD45RO−CD62L+) to central memory (CD45RO+CD62L+) and in the level of CD4 central memory T-cell subpopulations. A method of diagnosing autoimmunity and its progressiveness, more specifically diabetes, pre-diabetes, a susceptibility to diabetes mellitus, or the level of effectiveness of therapy/intervention modality for one or more of such conditions in a subject can be conducted by determining level of CD4 naïve (CD45RO−CD62L+) T-cells by immunofluorescence analysis of a sample extracted from a subject; determining level of CD4 central memory (CD45RO+CD62L+) T-cells by immunofluorescence analysis of a sample extracted from a subject, and quantitatively relating the levels of the CD4 naïve and central memory T-cells, wherein a low ratio of CD4 naïve T-cells to CD4 central memory T-cells and/or high CD4 central memory T-cell indicates autoimmunity, a susceptibility to autoimmunity, diabetes, pre-diabetes, a susceptibility to diabetes mellitus or ineffectiveness of a treatment for one or more of such conditions.
申请公布号 KR20150022878(A) 申请公布日期 2015.03.04
申请号 KR20147036002 申请日期 2013.05.24
申请人 ORBAN BIOTECH LLC 发明人 ORBAN TIHAMER
分类号 G01N33/50;A61K45/00;A61P5/50;A61P37/00;G01N15/14;G01N21/64;G01N33/533 主分类号 G01N33/50
代理机构 代理人
主权项
地址